Jim Cramer Believes Johnson & Johnson’s Earnings Should Be the Strongest Among Pharmaceuticals

Johnson & Johnson (NYSE:JNJ) is one of the stocks in Jim Cramer’s game plan for this week. Cramer expects the most from JNJ out of all the companies in the pharmaceutical industry, as he commented:

“Beyond the banks, we hear from Johnson & Johnson, which should have the strongest numbers of any pharmaceutical company. The stock shrugged off a bad loss in one of those talc lawsuits where the plaintiff accused J&J of knowingly selling a product that contained a carcinogen, asbestos. I think that the stock didn’t go down, but actually went up… decided the stock’s finally stopped being hostage to these interminable lawsuits.”

Gil C/Shutterstock.com

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and markets healthcare products across pharmaceuticals and medical technologies. During the October 1 episode, Cramer highlighted his interview with the company’s CEO and said:

“What else might work? Last Friday on the show, we had Joaquin Duato. He’s the CEO of Johnson & Johnson, and he told a remarkable story about game-changing cancer drugs and medical devices, especially their excellent cardio products. Now, I’ve been worried about the talc lawsuits that they have, but I believe the risk from the asbestos and the baby powder litigation has crested as J&J’s been winning the cases, and it’s planning to keep fighting them one by one. Eventually, I bet the plaintiffs will realize it’s just too costly to keep on taking J&J.”

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.